European Leukemia Trial Registry
Trial: MT103-211

More Details
Title Phase II Trial with Blinatumomab in relapsed/refractory B-precursor ALL
Scientific Title An open label, multicenter, phase II study to evaluate efficacy and safety of the BiTE antibody blinatumomab in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL)
Short Title MT103-211
Trialgroup GMALL
Type of Trial multicentric, single-group, open-label
Disease Acute lymphoblastic leukemia(ALL) B-Precursor ALL
Age >= 18 years
Status Closed
Start of Recruitment 05.12.2011
Leader Topp, Prof. Dr. med., Max
Contactperson

principal investigator
Topp, Prof. Dr. med., Max
Tel: +49 (0)931 201 70490
Fax: +49 (0)931 201 70841
Email: topp_m@klinik.uni-wuerzburg.de

Shortprotocol Shortprotocol
Remark For further information regarding the participating sites of the MT 103-211 trial in Europe please visit www.leukemia-net.org/content/leukemias/all/all_trials/mt103_211/
created 13.12.2011 Johannes Kraus
changed 03.05.2018 Student Studienregister
ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org